Abstract
Colorectal cancer is the third most frequently diagnosed cancer in men and the second most frequent in women, with a mortality of approximately half the incidence. Currently, there is no specific consensus regarding standard treatments for colorectal cancer, and new and effective treatment regimens are yet to be developed. Cabazitaxel (CTX), a derivative of paclitaxel, has better anticancer activity than paclitaxel and docetaxel, and has low structural affinity with the MDR1 efflux pump, which offers the advantage of overcoming multidrug resistance. However, the adverse effects and poor stability impede its clinical applications; therefore, we synthesized a new block copolymer (MPEG2k-PCL10k) to prepare CTX nanoparticle formulations to enhance its biocompatibility and bioavailability. Compared with the CTX preparation Jevtana®, the drug loading, stability and antitumor efficacy of the nanoparticles were significantly improved, while the cytoxicity was notably reduced. The results indicate that CTX-MPEG2k-PCL10k nanoparticle preparations have high security and excellent anti-tumor effects, and has great application potential in the colorectal cancer therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
